AtriCure had its Relative Strength (RS) Rating upgraded from 88 to 91 Wednesday.
IBD's unique RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
While it's not currently an ideal time to jump in, see if the stock manages to offer and clear a proper buy point.
AtriCure showed 0% EPS growth last quarter, while sales growth came in at 18%.
AtriCure earns the No. 15 rank among its peers in the Medical-Systems/Equipment industry group. Intuitive Surgical, Brainsway ADR and Electromed are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
